IKS014 in geavanceerde solide tumoren die HER2 tot expressie brengen
Een fase 1-dosisescalatieonderzoek om de veiligheid, tolerantie, maximaal getolereerde dosis en voorlopige antineoplastische activiteit van IKS014, een op HER2 gericht antilichaamgeneesmiddelconjugaat (ADC), te bepalen bij deelnemers met gevorderde HER2+ vaste tumoren
This study will evaluate the recommended dose for further clinical development, safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of IKS014, a HER2 targeting antibody-drug conjugate, in patients with advanced solid tumors.
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
The study will consist of 2 parts: dose-escalation (Part 1) and dose-expansion (Part 2). The dose-escalation part (Part 1) of the study is to evaluate the safety and tolerability of increasing dose levels of IKS014 to establish a recommended phase 2 dose (RP2D); and the dose-expansion part (Part 2) of the study is to further evaluate the safety, pharmacokinetics/pharmacodynamics, and efficacy of IKS014 at the RP2D.
Studietype
Inschrijving (Geschat)
Fase
- Fase 1
Contacten en locaties
Studiecontact
- Naam: David Browning
- Telefoonnummer: +1-615-975-7776
- E-mail: david.browning@iksuda.com
Studie Locaties
-
-
New South Wales
-
Concord, New South Wales, Australië, 2139
- Werving
- Concord Repatriation General Hospital Medical Oncology Clinical Trials Unit
-
Hoofdonderzoeker:
- Tam Bui, MD
-
Sydney, New South Wales, Australië, 2109
- Werving
- Macquarie University
-
Hoofdonderzoeker:
- Dhanusha Sabanathan, MD
-
Westmead, New South Wales, Australië, 2145
- Werving
- Westmead Hospital
-
Hoofdonderzoeker:
- Adnan Nagrial, MD
-
-
Victoria
-
Frankston, Victoria, Australië, 3199
- Werving
- Peninsula & South Eastern Haematology and Oncology Group (PSEHOG)
-
Hoofdonderzoeker:
- Vinod Ganju, MD
-
Melbourne, Victoria, Australië, 3004
- Werving
- Alfred Health
-
Hoofdonderzoeker:
- Malaka Ameratunga, MD
-
-
Western Australia
-
Nedlands, Western Australia, Australië, 6009
- Werving
- Linear Clinical Research
-
Hoofdonderzoeker:
- Peter Lau, MD
-
-
-
-
-
Auckland, Nieuw-Zeeland
- Werving
- Auckland City Hospital
-
Hoofdonderzoeker:
- Jane So, MBChB
-
-
-
-
-
Singapore, Singapore
- Werving
- National Cancer Centre Singapore
-
Hoofdonderzoeker:
- Jing Ying Tira Tan, MBBS
-
Singapore, Singapore
- Werving
- Tan Tock Seng Hospital
-
Hoofdonderzoeker:
- Yue Ming Valerie Heong, MBBS
-
-
-
-
California
-
Newport Beach, California, Verenigde Staten, 92663
- Werving
- Hoag Memorial Hospital Presbyterian
-
Hoofdonderzoeker:
- Monica Mita, MD
-
-
Massachusetts
-
Boston, Massachusetts, Verenigde Staten, 02215
- Werving
- Dana Farber Cancer Institute
-
Hoofdonderzoeker:
- Nancy Lin, MD
-
-
Tennessee
-
Nashville, Tennessee, Verenigde Staten, 37203
- Werving
- Tennessee Oncology
-
Hoofdonderzoeker:
- Jeffrey Russell, MD
-
-
Texas
-
Fort Worth, Texas, Verenigde Staten, 76104
- Werving
- START Dallas - Fort Worth
-
Hoofdonderzoeker:
- Henry Xiong, MD
-
Contact:
- Hope Team
- E-mail: hopeteam@startresearch.com
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Key Inclusion Criteria:
-
HER2 positive solid tumors with expression defined as IHC3+, IHC2+/ISH+, or low HER2 expression defined as IHC2+ (ISH-) or IHC1+ (ISH- /+ or untested).
-
Participants with HR positive BC must have received prior treatment with a CDK4/6 inhibitor, in countries where this is standard therapy.
-
Platelets ≥ 75,000 /mcL
-
Hemoglobin ≥ 9.0 g/dL
-
Absolute neutrophil count ≥ 1000/mcL
-
No administration of granulocyte colony-stimulating factor (G-CSF) is allowed within 2 weeks prior to first study drug administration
-
Creatinine clearance > 45/mL/min (using the Cockcroft-Gault equation)
-
Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) ≤ 3 x institutional upper limit of normal (ULN) ≤ 5 x ULN if liver metastases present
-
Total bilirubin ≤ 1.5 x ULN if no liver metastases or < 3 x ULN with Gilbert's Syndrome or liver metastases at baseline
-
Albumin > 2.5 g/dL
-
Prothrombin time or international normalized ratio (INR) and either partial thromboplastin time (PTT) or activated (a) PTT ≤ 1.5 x ULN, ≤ 3 x institutional ULN if anticoagulated.
-
Must have adequate treatment washout period before trial treatment, defined as: Major surgery (≥ 4 weeks) and radiation therapy (≥ 3 weeks; in case of palliative radiation ≥ 2 weeks)
-
Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 (or equivalent Karnofsky PS)
-
Part 2 Dose Expansion Cohorts May Include:
- Advanced or metastatic BC that is confirmed HER2-positive defined as IHC 3+ or IHC 2+ and evidence of HER2 amplification by ISH, as per ASCO-CAP and previously treated with at least two HER2 directed treatments.
- Advanced or metastatic BC that has low HER2 expression defined as IHC2+ (ISH-) or IHC1+ (ISH-/+ or untested) and previously treated with at least 1 prior line of therapy which may include chemotherapy and/or a HER2 directed ADC.
- Advanced or metastatic GC or GEJ cancer that is confirmed HER2-positive defined as IHC 3+ or IHC 2+ and evidence of HER2 amplification by ISH as per ASCO-CAP and previously treated with at least 1 prior line of therapy, which may include chemotherapy and/or a HER2 directed ADC.
- Advanced or metastatic solid tumor that has been treated with standard of care therapy and is HER2 positive (HER2 IHC3+) as per ASCO-CAP or metastatic NSCLC (that has been treated with standard of care therapy) with a known activating HER2 (ERBB2) mutation.
- Advanced or metastatic adenocarcinoma of the Esophagus that has been treated with at least one prior line of standard treatment, which may have included a HER2-directed therapy. The tumor must be HER2 positive defined either HER2 IHC3+ or HER2 IHC 2+/ISH+.
Key Exclusion Criteria:
-
History of (noninfectious) ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at Screening.
-
Any clinically apparent ≥ Grade 2 pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder (i.e., pulmonary emboli within three months of the trial enrollment, severe asthma, severe chronic obstructive pulmonary disease [COPD], restrictive lung disease, pleural effusion, etc.), and any autoimmune, connective tissue or inflammatory disorders with potential pulmonary involvement (e.g., rheumatoid arthritis, Sjogren's, sarcoidosis), or prior pneumonectomy.
-
Current evidence of ≥ Grade 2 keratitis or other corneal abnormality.
-
Evidence of a clinically significant (≥ Grade 2) abnormality on slit-lamp examination or other clinically significant ophthalmologic finding, as determined by an ophthalmologist.
-
Evidence of clinically significant (≥ Grade 2) confluent superficial keratitis, a corneal epithelial defect, a corneal ulcer, or stromal opacity.
-
Participant must not use contact lenses while participating in this study.
-
Central nervous system metastatic disease unless treated with definitive local therapy (surgical resection, stereotactic radiotherapy, or whole brain radiotherapy) and participant is clinically, radiologically and neurologically stable for at least 4 weeks prior to the first dose of study drug not on steroid therapy or are on a stable or decreasing dose of steroids for at least 7 days prior to first dose of study drug. Prophylactic anticonvulsant medications are allowed.
-
Active second malignancy or history of another malignancy within the last 2 years with the exception of:
- Treated, non-melanoma skin cancers
- Treated carcinoma in situ (CIS) (e.g., breast, cervix)
- Controlled, superficial carcinoma of the urinary bladder
- T1a or b carcinoma of the prostate treated according to local standard of care, with prostate specific antigen (PSA) within normal limits (WNL) for the institution
- Papillary thyroid carcinoma Stage I treated surgically for cure
-
Clinically significant cardiovascular disease or condition
-
Clinically significant liver disease
-
Any other serious/active/uncontrolled infection, any infection requiring parenteral antibiotics, or unexplained fever > 38ºC within 2 weeks prior to first trial drug administration.
-
Any other serious, life-threatening, or unstable preexisting medical condition (aside from the underlying malignancy), including significant organ system dysfunction, or clinically significant laboratory abnormality(ies), which, in the opinion of the Investigator, would either compromise the participant's safety or interfere with obtaining informed consent, compliance with trial procedures, or evaluation of the safety of the trial drug.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Sequentiële toewijzing
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Dose Escalation Cohort (Part 1)
Each patient will receive repeat doses (by intravenous (IV) infusions) on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criteria is met. |
IKS014 is a human monoclonal antibody (Ab) targeting HER2 linked to monomethyl auristatin F (MMAF) cytotoxic agent. |
|
Experimenteel: Dose Expansion: HER2+ Breast Cancer Participants
Each patient will receive IKS014 at the recommended dose defined in Part 1 on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criteria is met. |
IKS014 is a human monoclonal antibody (Ab) targeting HER2 linked to monomethyl auristatin F (MMAF) cytotoxic agent. |
|
Experimenteel: Dose Expansion: HER2 Low Breast Cancer Participants
Each patient will receive IKS014 at the recommended dose defined in Part 1 on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criteria is met. |
IKS014 is a human monoclonal antibody (Ab) targeting HER2 linked to monomethyl auristatin F (MMAF) cytotoxic agent. |
|
Experimenteel: Dose Expansion: HER2+ Gastric Cancer or Gastro-esophageal Junction Participants
Each patient will receive IKS014 at the recommended dose defined in Part 1 on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criteria is met. |
IKS014 is a human monoclonal antibody (Ab) targeting HER2 linked to monomethyl auristatin F (MMAF) cytotoxic agent. |
|
Experimenteel: Dose Expansion: HER2 Low Gastric Cancer or Gastro-esophageal Junction Participants
Each patient will receive IKS014 at the recommended dose defined in Part 1 on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criteria is met. |
IKS014 is a human monoclonal antibody (Ab) targeting HER2 linked to monomethyl auristatin F (MMAF) cytotoxic agent. |
|
Experimenteel: Dose Expansion: HER2 Solid Tumor Cancer Participants
Each patient will receive IKS014 at the recommended dose defined in Part 1 on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criteria is met. |
IKS014 is a human monoclonal antibody (Ab) targeting HER2 linked to monomethyl auristatin F (MMAF) cytotoxic agent. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Recommended Phase 2 Dose (Part 1)
Tijdsspanne: Up to 24 months
|
Based on tolerability, preliminary anti-tumor activity, and pharmacokinetics |
Up to 24 months
|
|
Objective Response Rate (Part 2)
Tijdsspanne: Up to 24 months
|
Anti-tumor activity will be assessed by RECIST 1.1 |
Up to 24 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Objective Response Rate (Part 1)
Tijdsspanne: Up to 24 months
|
Anti-tumor activity will be assessed by RECIST 1.1 |
Up to 24 months
|
|
Plasma Concentrations of IKS014 (Part 1 and 2)
Tijdsspanne: Up to 48 months
|
Pharmacokinetic parameters will be determined from observed concentrations of IKS014 |
Up to 48 months
|
|
Evaluation of the immunogenicity of IKS014 (Part 1 and 2)
Tijdsspanne: Up to 48 months
|
Occurrence of ADA measured in serum at selected timepoints during the study |
Up to 48 months
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie directeur: James O'Leary, MD, Iksuda Therapeutics
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- IKS014-01
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .